HER2Amplification in Gastroesophageal Adenocarcinor

American Journal of Clinical Pathology
137, 583-594
DOI: 10.1309/ajcpxqvs6yghpdcy

Citation Report

#	Article	IF	Citations
1	Tumors of the digestive system. , 2000, , 133-182.		0
2	HER2 Assessment in Upper Gastrointestinal Tract Adenocarcinoma. Surgical Pathology Clinics, 2013, 6, 391-403.	0.7	4
3	HER2 Amplification or Overexpression in Upper GI Tract and Breast Cancer with Clinical Diagnosis and Treatment. , 0, , .		2
4	The Degree of Segmental Aneuploidy Measured by Total Copy Number Abnormalities Predicts Survival and Recurrence in Superficial Gastroesophageal Adenocarcinoma. PLoS ONE, 2014, 9, e79079.	1.1	24
5	HER2 in solid tumors: more than 10 years under the microscope; where are we now?. Future Oncology, 2014, 10, 1469-1486.	1.1	39
6	Recycling and Long-Term Storage of Fluorescence In Situ Hybridization Slides. American Journal of Clinical Pathology, 2014, 141, 374-380.	0.4	3
7	HER2 testing in gastric and gastroesophageal junction adenocarcinomas. Diagnostic Histopathology, 2014, 20, 247-256.	0.2	0
8	A critical review of HER2-positive gastric cancer evaluation and treatment: From trastuzumab, and beyond. Cancer Letters, 2014, 351, 30-40.	3.2	56
9	Association between HER2 status in gastric cancer and clinicopathological features: a retrospective study using whole-tissue sections. BMC Gastroenterology, 2015, 15, 157.	0.8	22
10	Human epidermal growth factor receptor 2 overexpression and amplification in endoscopic biopsies and resection specimens in esophageal and junctional adenocarcinoma. Ecological Management and Restoration, 2015, 28, 380-385.	0.2	6
11	HER2 Testing in Gastric and Gastroesophageal Adenocarcinomas. Advances in Anatomic Pathology, 2015, 22, 194-201.	2.4	23
12	Human epidermal growth factor receptor 2 testing in gastric and gastroesophageal junction adenocarcinomas: role of the gastroenterologist. Gastrointestinal Endoscopy, 2015, 81, 977-982.	0.5	3
13	Evaluation of HER2/neu Status by Immunohistochemistry Using Computer-Based Image Analysis and Correlation With Gene Amplification by Fluorescence In Situ Hybridization Assay: A 10-Year Experience and Impact of Test Standardization on Concordance Rate. Archives of Pathology and Laboratory Medicine, 2015, 139, 922-928.	1.2	18
14	MiR-193a-5p/ERBB2 act as concurrent chemoradiation therapy response indicator of esophageal squamous cell carcinoma. Oncotarget, 2016, 7, 39680-39693.	0.8	30
15	Metabolic Signature on ¹⁸F-FDG PET/CT, HER2 Status, and Survival in Gastric Adenocarcinomas. Journal of Nuclear Medicine Technology, 2016, 44, 234-238.	0.4	8
16	HER2Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma. American Journal of Clinical Pathology, 2016, 146, 647-669.	0.4	46
17	HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline From the College of American Pathologists, American Society for Clinical Pathology, and American Society of Clinical Oncology. Archives of Pathology and Laboratory Medicine, 2016, 140, 1345-1363.	1.2	112
18	PD-L1 expression is associated with massive lymphocyte infiltration and histology in gastric cancer. Human Pathology, 2016, 55, 182-189.	1.1	58

#	Article	IF	Citations
19	Effect of EGFR and p-AKT Overexpression on Chromosomal Instability in Gastric Cancer. Annals of Surgical Oncology, 2016, 23, 1986-1992.	0.7	13
20	HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline From the College of American Pathologists, American Society for Clinical Pathology, and the American Society of Clinical Oncology. Journal of Clinical Oncology, 2017, 35, 446-464.	0.8	273
21	Digital Image Analysis of HER2 Immunostained Gastric and Gastroesophageal Junction Adenocarcinomas. Applied Immunohistochemistry and Molecular Morphology, 2017, 25, 320-328.	0.6	7
22	Digital image analysis of HER2 immunohistochemistry in gastricâ€•and oesophageal adenocarcinoma: a validation study on biopsies and surgical specimens. Histopathology, 2018, 72, 191-200.	1.6	15
23	Extreme chromosome 17 copy number instability is a prognostic factor in patients with gastroesophageal adenocarcinoma: A retrospective cohort study. Genes Chromosomes and Cancer, 2018, 57, 28-34.	1.5	1
24	Tumor Heterogeneity Index to Detect Human Epidermal Growth Factor Receptor 2 Amplification by Next-Generation Sequencing. Journal of Molecular Diagnostics, 2019, 21, 612-622.	1.2	9
25	The correlation between molecular pathological profiles and metabolic parameters of 18F-FDG PET/CT in patients with gastroesophageal junction cancer. Abdominal Radiology, 2020, 45, 312-321.	1.0	5
26	Assessment of HER2 Status Using Immunohistochemistry (IHC) and Fluorescence In Situ Hybridization (FISH) Techniques in Mucinous Epithelial Ovarian Cancer: A Comprehensive Comparison between ToGA Biopsy Method and ToGA Surgical Specimen Method. PLoS ONE, 2015, 10, e0142135.	1.1	12
27	Alterations of biomarker profiles after neoadjuvant chemotherapy in breast cancer: tumor heterogeneity should be taken into consideration. Oncotarget, 2015, 6, 36894-36902.	0.8	29
28	Phase I/IIa Trial of BMS-986148, an Anti-mesothelin Antibodyâ€“drug Conjugate, Alone or in Combination with Nivolumab in Patients with Advanced Solid Tumors. Clinical Cancer Research, 2022, 28, 95-105.	3.2	24
29	MiR-200c suppresses the migration of retinoblastoma cells by reversing epithelial mesenchymal transition. International Journal of Ophthalmology, 2017, 10, 1195-1202.	0.5	12
30	A study of human epidermal growth factor receptor-2 (HER-2) in carcinoma esophagus (Single) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Molecular and Immuno Oncology, 0, 5, 108-112.	0.0	0
31	Association between HER2 heterogeneity and clinical outcomes of HER2-positive gastric cancer patients treated with trastuzumab. Gastric Cancer, 2022, 25, 794-803.	2.7	7
32	Deviating HER2 test results in gastric cancer: analysis from the prospective multicenter VARIANZ study. Journal of Cancer Research and Clinical Oncology, 0, , .	1.2	0